Prof. Zhuravlyova L.V., PHD Rogachova T.A. Kharkiv national medical university. Department of internal medicine № 3.

The social importance of obesity is determined by high risk of disability of young patients and decrease in overall life expectancy due to frequent development of severe co-morbidities. Proper goal setting in the treatment of obesity includes 5-10% reduction in body weight for 6 months, stabilization of the achieved weight and prevention of its relapse, reduction in the risk of complications, remission or control of existing complications. In this review, modern approaches to diagnostics of pathological conditions, associated with obesity, modern methods of treatment, including diet and exercise therapy, behavioral therapy, medication therapy and bariatric surgery are considered.

Key Words: obesity, complications of obesity, diet and exercise therapy, behavioral therapy, medication therapy and bariatric surgery.

https://dx.doi.org/10.15407/internalmed2017.02.031

Zhuravlyova LV, Rogachova TA. [Obesity as multidisciplinary problem – clinical picture, diagnostics and treatment]. z. vnutr. simejnoi med. 2017;2:31-36. Russian.

Download.PDF

1. Mitchenko EI, Korpachev VV, Lutaj MI, Man’kovskij BN. Diagnostika i lechenie metabolicheskogo sindroma, sakharnogo diabeta, prediabeta i serdechno-sosudistykh zabolevanii. International Journal of Endocrinology. 2008;3(15):15. Russian

2. Ahima R. Digging deeper into obesity. J Clin Invest. 2011 Jun 1;121(6):2076–79. doi: 10.1172/JCI58719 https://doi.org/10.1172/JCI58719

3. Ahima RS, Prabakaran D, Mantzoros C, Qu D, Lowell B, Maratos-Flier E, Flier JS. Role of leptin in the neuroendocrine response to fasting. Nature. 1996 Jul 18;382(6588):250-2. PMID: 8717038 DOI: 10.1038/382250a0 https://doi.org/10.1038/382250a0

4. William T Cefalu. American Diabetes Association. Standarts of medical care in diabetes. 2016;39(1).

5. Canale MP, Manca di Villahermosa S, Martino G, Rovella V, Noce A, De Lorenzo A, Di Daniele N. Obesity-Related Metabolic Syndrome: Mechanisms of Sympathetic Overactivity. Int J Endocrinol. 2013; 2013: 865965. PMCID: PMC3833340

6. Chazova I, Markus P. Schlaich. Improved Hypertension Control with the Imidazoline Agonist Moxonidine in a Multinational Metabolic Syndrome Population: Principal Results of the MERSY Study. Int J Hypertens. 2013; 2013: 541689. PMCID: PMC3596898

7. Cole TJ, Lobstein T. Extended international (IOTF) body mass index cut-offs for thinness, overweight and obesity. Pediatr Obes. 2012 Aug;7(4):284-94. doi: 10.1111/j.2047-6310.2012.00064.x. Epub 2012 Jun 19. https://doi.org/10.1111/j.2047-6310.2012.00064.x

8. Després JP, Couillard C, Gagnon J, Bergeron J, Leon AS, Rao DC, Skinner JS, Wilmore JH, Bouchard C. Race, visceral adipose tissue, plasma lipids, and lipoprotein lipase activity in men and women: the Health, Risk Factors, Exercise Training, and Genetics (HERITAGE) family study. Arterioscler Thromb Vasc Biol. 2000 Aug;20(8):1932-8. PMID: 10938014 https://doi.org/10.1161/01.ATV.20.8.1932 PMid:10938014

9. Dirkx E, Schwenk RW, Glatz JF, Luiken JJ, van Eys GJ. High fat diet induced diabetic cardiomyopathy. Prostaglandins Leukot Essent Fatty Acids. 2011 Nov;85(5):219-25. doi: 10.1016/j.plefa.2011.04.018. Epub 2011 May 14. https://doi.org/10.1016/j.plefa.2011.04.018

10. Fabbrini E, Tamboli RA, Magkos F, Marks-Shulman PA, Eckhauser AW, Richards WO, Klein S, Abumrad NN. Surgical removal of omental fat does not improve insulin sensitivity and cardiovascular risk factors in obese adults. Gastroenterology. 2010 Aug;139(2):448-55. doi: 10.1053/j.gastro.2010.04.056. Epub 2010 May 7. https://doi.org/10.1053/j.gastro.2010.04.056

11. Farooqi IS, O’Rahilly S. 20 years of leptin: human disorders of leptin action. J Endocrinol. 2014 Oct;223(1):T63-70. doi: 10.1530/JOE-14-0480. https://doi.org/10.1530/JOE-14-0480

12. Gahagan S. Development of eating behavior: biology and context. J Dev Behav Pediatr. 2012 Apr;33(3):261-71. doi: 10.1097/DBP.0b013e31824a7baa. https://doi.org/10.1097/DBP.0b013e31824a7baa

13. Georgiadou D, Sergentanis TN, Nixon A, Diamantis T, Tsigris C, Psaltopoulou T. Efficacy and safety of laparoscopic mini gastric bypass. A systematic review. Surg Obes Relat Dis. 2014 Sep-Oct;10(5):984-91. doi: 10.1016/j.soard.2014.02.009. Epub 2014 Feb 15. https://doi.org/10.1016/j.soard.2014.02.009

14. Guerra F, Mancinelli L, Angelini L, Fortunati M, Rappelli A, Dessì-Fulgheri P, Sarzani R. The association of left ventricular hypertrophy with metabolic syndrome is dependent on body mass index in hypertensive overweight or obese patients. PLoS One. 2011 Jan 31;6(1):e16630. doi: 10.1371/journal.pone.0016630. https://doi.org/10.1371/journal.pone.0016630

15. Holland WL, Bikman BT, Wang LP, Yuguang G, Sargent KM, Bulchand S, Knotts TA, Shui G, Clegg DJ, Wenk MR, Pagliassotti MJ, Scherer PE, Summers SA. Lipid-induced insulin resistance mediated by the proinflammatory receptor TLR4 requires saturated fatty acid-induced ceramide biosynthesis in mice. J Clin Invest. 2011 May;121(5):1858-70. doi: 10.1172/JCI43378. Epub 2011 Apr 1. https://doi.org/10.1172/JCI43378

16. Kaplan L. Pharmacologic therapies for obesity. Gastroenterol Clin North Am. 2010;39(1):69–79. PMID: 15823441, DOI: 10.1016/j.gtc.2004.12.002 https://doi.org/10.1016/j.gtc.2004.12.002

17. Krupicka J, Soucek M, Chroust K. The efficacy and safety of moxonidine in patients with metabolic syndrome (the O.B.E.Z.I.T.A. trial). Vnitr Lek. 2011 Jun;57(6):541-5. PMID: 21751539 PMid:21751539

18. Lee W. Laparoscopic Roux-en-Y vs mini-gastric bypass for the treatment of morbid obesity: 10 – years experience. Obes Surg. 2012; 22(12):1827-34. https://doi.org/10.1007/s11695-012-0726-9 PMid:23011462

19. Lê KA, Mahurkar S, Alderete TL, Hasson RE, Adam TC, Kim JS, Beale E, Xie C, Greenberg AS, Allayee H, Goran MI. Subcutaneous adipose tissue macrophage infiltration is associated with hepatic and visceral fat deposition, hyperinsulinemia, and stimulation of NF-κB stress pathway. Diabetes. 2011 Nov;60(11):2802-9. doi: 10.2337/db10-1263. https://doi.org/10.2337/db10-1263

20. López M. Hypothalamic Leptin Resistance: From BBB to BBSome. PLoS Genet. 2016 May;12(5): e1005980. PMC4858138 https://doi.org/10.1371/journal.pgen.1005980 PMid:27149508 PMCid:PMC4858138

21. Myers MG, Cowley MA, Münzberg H. Mechanisms of leptin action and leptin resistance. Annu Rev Physiol. 2008;70:537-56. https://doi.org/10.1146/annurev.physiol.70.113006.100707 PMid:17937601

22. Martin G. Myers, Jr., Steven B. Heymsfield, Carol Haft, Barbara B. Kahn, Maren Laughlin, Rudolph L. Leibel, Matthias H. Tschöp, Jack A. Yanovski. Defining Clinical Leptin Resistance – Challenges and Opportunities. Cell Metab. 2012 Feb 8;15(2):150–156. doi: 10.1016/j.cmet.2012.01.002 https://doi.org/10.1016/j.cmet.2012.01.002

23. Myers MG Jr, Münzberg H, Leinninger GM, Leshan RL. The geometry of leptin action in the brain: more complicated than a simple ARC. Cell Metab. 2009 Feb;9(2):117-23. doi: 10.1016/j.cmet.2008.12.001. https://doi.org/10.1016/j.cmet.2008.12.001

24. Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet. 2007 Jan 6;369(9555):71-7. https://doi.org/10.1016/S0140-6736(07)60033-6

25. Richard N. Redinger. The Pathophysiology of Obesity and Its Clinical Manifestations. Gastroenterol Hepatol (N Y). 2007 Nov;3(11):856–63.

26. Shuster A, Patlas M, Pinthus JH, Mourtzakis M. The clinical importance of visceral adiposity: a critical review of methods for visceral adipose tissue analysis. Br J Radiol. 2012 Jan;85(1009):1-10. doi: 10.1259/bjr/38447238. Epub 2011 Sep 21. https://doi.org/10.1259/bjr/38447238

27. Sjöström L. A computer-tomography based multicompartment body composition technique and anthropometric predictions of lean body mass, total and subcutaneous adipose tissue. Int J Obes. 1991 Sep;15 Suppl 2:19-30. PMid:1794934

28. James R. Sowers, Adam Whaley-Connell, Melvin R. Haydenc. The Role of Overweight and Obesity in the Cardiorenal Syndrome. Cardiorenal Med. 2011 Jan; 1(1):5–12. PMC3101516 https://doi.org/10.1159/000322822 PMid:22258461 PMCid:PMC3101516

29. Srozhidinova N, Tukhtayev A. Moxonidine efficiency in hypertension treatment in patients with metabolic syndrome. Arterial Hypertension. 2013;3(29).

30. Stiefel P, Vallejo-Vaz AJ, García Morillo S, Villar J. Role of the Renin-Angiotensin System and Aldosterone on Cardiometabolic Syndrome. Int J Hypertens. 2011;685238. PMC3139197 https://doi.org/10.4061/2011/685238

31. Vaněčková I, Maletínská L, Behuliak M, Nagelová V, Zicha J, Kuneš J. Obesity-related hypertension: possible pathophysiological mechanisms. J Endocrinol. 2014 Dec;223(3):63-78. doi: 10.1530/JOE-14-0368. https://doi.org/10.1530/JOE-14-0368

32. Vasselli J. The role of dietary components in insulin resistance. Advances in nutrition. 2012;3;736-8. doi: 10.3945/an.112.002659 https://doi.org/10.3945/an.112.002659

33. Wang Y, Rimm EB, Stampfer MJ, Willett WC, Hu FB. Comparison of abdominal adiposity and overall obesity in predicting risk of type 2 diabetes among men. Am J Clin Nutr. 2005 Mar;81(3):555-63. PMID: 15755822 PMid:15755822

34. Wilson PW, D’Agostino RB, Sullivan L, Parise H, Kannel WB. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med. 2002 Sep 9;162(16):1867-72. PMID: 12196085 https://doi.org/10.1001/archinte.162.16.1867 PMid:12196085